Table 5 Comparison of Mean PASI Score and BSA Reductions, along with Treatment Costs, in Psoriasis Patients Treated with Risankizumab (N = 30) vs. Adalimumab (N = 40)
| Â | Risankizumab | Adalimumab | Mean difference (95% confidence interval) |
|---|---|---|---|
Cost of treatment (USD), mean ± SD | 16638.33 ± 5086.63 | 9433.20 ± 1768.37 | 7,205.13(5981.39–9063.56) |
Difference in PASI (%) | 87.373 ± 25.938 | 74.499 ± 36.143 | 12.88(1.271–24.934) |